Creo Medical welcomes Ivonne Cantu to its Board as Independent Director

– UK, Chepstow –  Creo Medical Group Plc (LON: CREO), a medical device company focused on the emerging field of surgical endoscopy, today announced the appointment of Ivonne Cantu to its Board as an Independent Non-Executive Director with effect from 1 February 2020 and will become Chair of the  Remuneration Committee.

“We are pleased to welcome Ivonne to the Board. She has known Creo since we were a private company and brings a wealth of experience from her career in the City, which we are confident will make a major contribution to the success of Creo,” said Charles Spicer, Non- Executive Chairman.

About Ivonne Cantu

Ivonne has extensive experience in corporate finance acting as corporate finance adviser to the UK and international companies for more than 20 years at Cenkos Securities plc and previously at Merrill Lynch. Ivonne is currently Director of Investor Relations and Corporate Development at Benchmark Holdings plc, the AIM-listed aquaculture technology company. Ivonne holds a BSc in Engineering from Universidad Panamericana and an MBA from the Wharton School of Business.

About Creo Medical

Creo Medical, founded in 2003, is a medical device company focused on the development and commercialisation of minimally invasive surgical devices, by bringing advanced energy to endoscopy. The Company’s mission is to improve patient outcomes by applying microwave and RF energy to surgical endoscopy. Creo has developed CROMA, an electrosurgical Advanced Energy Platform that combines bipolar radiofrequency for precise localised cutting and microwave for controlled coagulation. This technology provides clinicians with flexible, accurate and controlled surgical solutions.

The Company’s strategy is to bring its CROMA Advanced Energy Platform powered by unique full-spectrum adaptive technology to market enabling a suite of medical devices which the Company has designed, initially for the emerging field of GI therapeutic endoscopy, an area with high unmet needs. The CROMA Advanced Energy platform will be developed further for bronchoscopy and laparoscopy procedures. The Company believes its technology can impact the landscape of surgery and endoscopy by providing a safer, less-invasive and more cost-efficient option of treatment.

For more information: https://investors.creomedical.com

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.